1. United Kingdom Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Hemogenyx Pharmaceuticals Plc

Hemogenyx Pharmaceuticals Plc

HEMO.L
Hemogenyx Pharmaceuticals PlcGB flagLondon Stock Exchange
790.00
GBp
-7.00
- -
53.72MMarket Cap
Hemogenyx Pharmaceuticals Plc
HEMO.L
(London Stock Exchange)

Recent

price

790.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
-0.04
-2.89
-3.63
-1.72
-1.61
-2.01
-2.64
-1.62
-2.37
-1.7
-2.2
Basic EPS, GAAP
-0.04
-4.48
-0.79
-1.53
-1.34
-1.9
-1.78
-1.36
-2.2
-1.26
-0.78
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.27
2.24
0.91
-1.05
-2.6
-3.57
-1.72
-2.99
-4.27
-8.9
-8.71
Book Value per Share
0.27
0.65
2.88
0.76
-0.68
0.6
3.99
1.14
0.82
0.11
0.22
Tangible Book Value per Share
- -
- -
1
1
1
1
2
2
3
3
4
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
1
1
1
Depreciation Expense
- -
- -
-2
-2
-1
-2
-5
-4
-7
-6
-10
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
2
2
- -
- -
7
2
1
- -
1
Working Capital
- -
- -
- -
1
1
- -
- -
3
3
2
2
LT Debt
- -
- -
2
1
- -
1
8
3
3
1
1
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-230.13
-492.51
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
141.75%
144.59%
34.09%
Free Cash Flow
1,182.7%
21.58%
-16.89%
Net Income, GAAP
806.26%
49.75%
73.7%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-2.37
2024
- -
- -
- -
- -
-1.7
2025
- -
- -
- -
- -
-2.2

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Surrozen, Inc. (SRZN)
Magenta Therapeutics, Inc. (MGTA)
Arcellx, Inc. (ACLX)
TCR2 Therapeutics Inc. (TCRR)
Financière de Tubize S.A. (TUB.BR)
Asymchem Laboratories (Tianjin) Co., Ltd. (002821.SZ)
Business
Hemogenyx Pharmaceuticals Plc is a clinical-stage biotechnology company specializing in the discovery, development, and commercialization of innovative treatments for blood cancers, autoimmune diseases, and viral infections. The company’s core product portfolio includes the HG-CT-1 CAR-T cell therapy for relapsed or refractory acute myeloid leukemia (R/R AML), currently in Phase I clinical trials; the Chimeric Bait Receptor (CBR) platform, which programs immune cells to target viral pathogens; and the CDX bispecific CD3-FLT3 antibody and CAR-T therapies designed for patient conditioning in bone marrow transplantation. Hemogenyx operates primarily in the United Kingdom and the United States, with headquarters in London and US subsidiaries in New York. Founded in 2013 and publicly listed on the London Stock Exchange since 2014, Hemogenyx focuses on innovative cell therapies and immunotherapies within the pharmaceuticals and biotechnology industry. Recent significant developments include the successful initiation of Phase I clinical trials for HG-CT-1 with expansion to include pediatric patients, following FDA clearance; progression of the CBR antiviral/biodefense platform with new patent filings; a collaboration with Kure.ai to develop an ultrafast CAR-T manufacturing process; and multiple funding rounds raising millions of British pounds to support clinical and product development efforts. The company continues to advance its pipeline with strategic clinical site openings, updated trial protocols, and research collaborations to address critical unmet medical needs in hematologic oncology and infectious disease treatment. Hemogenyx Pharmaceuticals has established itself as a clinical-stage biotechnology entity committed to delivering breakthrough therapies for life-threatening blood disorders and related diseases with a focus on innovation, patient impact, and value creation for stakeholders. The company integrates its platform technologies and novel treatment candidates to expand therapeutic opportunities across global markets.